← Back to Search

Artificial Tears

Carboxymethylcellulose (CMC) Artificial Tears for Dry Eye Syndrome

Phase 4
Waitlist Available
Led By Yujia Zhou
Research Sponsored by University of Florida
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* Adults above age 18 of either sex who can self-administer artificial tears and return for follow-up at the UF Oaks Eye Clinic.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up assessed at day 1 and day 7, difference between day 1 and day 7 reported.
Awards & highlights

Summary

This trial is testing eye drops with a substance called CMC to see if it changes the bacteria in the eyes. Carboxymethylcellulose (CMC) is a common ingredient in artificial tears, used to improve eye hydration and reduce surface friction. The study involves people who use artificial tears and aims to understand how these drops might affect eye health.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~assessed at day 1 and day 7, difference between day 1 and day 7 reported.
This trial's timeline: 3 weeks for screening, Varies for treatment, and assessed at day 1 and day 7, difference between day 1 and day 7 reported. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Beta Diversity (Unweighted UniFrac)
Beta Diversity (Weighted UniFrac)
Species Diversity
+1 more
Secondary study objectives
Artificial Tear Use
Ocular Surface Disease Index Score

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Carboxymethylcellulose (CMC) Artificial TearsExperimental Treatment1 Intervention
Refresh brand artificial tears containing 0.5% carboxymethylcellulose will be self-administered three times a day in each eye by the participants for 1 week in the experimental arm.
Group II: Preservative-free, CMC-free Artificial TearsPlacebo Group1 Intervention
Systane brand artificial tears containing 0.4% polyethylene glycol 400 and 0.3% propylene glycol will be self-administered three times a day in each eye by the participants for 1 week in the control arm.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Carboxymethylcellulose (CMC) Artificial Tears
2022
Completed Phase 4
~80

Find a Location

Who is running the clinical trial?

University of FloridaLead Sponsor
1,380 Previous Clinical Trials
762,315 Total Patients Enrolled
Yujia ZhouPrincipal InvestigatorUniversity of Florida
~24 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top